More than 30 years after their introduction, growth hormone (GH) immunoassays showed the poorest inter-laboratory agreement of the various hormone assays evaluated in 1998 by the UK National External Quality Assessment Scheme, in which different laboratories using different assays reported that analyses of identical samples differed two- to threefold in value. There is therefore an urgent requirement and desire within the scientific community, particularly within centres diagnosing and treating GH deficiency and acromegaly, to resolve this problem and to develop a GH assay(s) that measures solely all of the relevant components of circulating GH immunoreactivity. The main confounders in the estimation of GH levels (now that the use of GH standards other than that recommended by the World Health Organization has largely been eliminated) are GH heterogeneity, anti-GH antiserum binding site specificity and interference from circulating high-affinity GH-binding protein (GHBP). The effects of these factors are closely related. The present study investigates these factors, focussing on the influence of GHBP and antibody binding site specificity on various assays for GH. The findings lead the authors to suggest that a solution to the problem may be to develop a GH assay that measures specifically and solely all serum 22 kDa GH, as this is the major circulating fraction and carries the dominant GH bioactivity.

Keywords:
Growth hormone, Growth hormone-binding protein, Immunoassays, Cut-off levels, Antibody specificity, Growth hormone receptor
1.
Levin PA, Chalew SA, Martin L, Kowarski AA: Comparison of assays for growth hormone using monoclonal or polyclonal antibodies for diagnosis of growth disorders. J Lab Clin Med 1987;109:85–88.
2.
Reiter EO, Morris AH, MacGillivray MH, Weber D: Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab 1988;66:68–71.
3.
Seth J, Hanning I, Bacon RR, Hunter WM: Quality of performance of assays for serum growth hormone in the United Kingdom (UK): Evidence from the UK external quality assessment scheme, 1980–1987. Clin Chim Acta 1988;174:171–183.
4.
Celniker AC, Chen AB, Wert RMJ, Sherman BM: Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469–476.
5.
Felder RA, Holl RW, Martha PJ, Bauler G, Hellman P, Wills MR, Thorner MO: Influence of matrix on concentrations of somatotropin measured in serum with commercial immunoradiometric assays. Clin Chem 1989;35:1423–1426.
6.
Chatelain P, Bouillat B, Cohen R, Sassolas G, Souberbielle JC, Ruitton A, Joly MO, Job JC: Assay of growth hormone levels in human plasma using commercial kits: Analysis of some factors influencing the results. Acta Paediatr Scand Suppl 1990;370:56–61.
7.
Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, Audi L: Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand Suppl 1990;370:63–70.
8.
Banfi G, Marinelli M, Pontillo M, Bonini P: Standardization with synthetic 22-kDa monomer human growth hormone reduces discrepancies between two monoclonal immunoradiometric assay kits. Clin Chem 1992;38:2107–2110.
9.
Chevenne D, Beau N, Leger J, Porquet D: Variability of serum human growth hormone levels in different commercial assays: Specificity of growth hormone-releasing hormone stimulation. Horm Res 1993;40:168–172.
10.
Barth JH, Smith JH, Clarkson P: Wide diversity in measurements of growth hormone after stimulation tests in short children are due to assay variability. Ann Clin Biochem 1995;32:369–372.
11.
Barth JH, Smith JH, Clarkson P: Interassay differences in growth hormone measurement in acromegaly. Ann Clin Biochem 1997;34:156–159.
12.
Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K: Growth-hormone (GH) assays: Influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 1997;43:950–956.
13.
Fisker S, Ebdrup L, Ørskov H: Influence of growth hormone binding protein on growth hormone estimation in different immunoassays. Scand J Clin Lab Invest 1998;58:373–381.
14.
Andersson AM, Ørskov H, Ranke MB, Shalet S, Skakkebæk NE: Interpretation of growth hormone provocative tests: Comparison of cut-off values in four European laboratories. Eur J Endocrinol 1995;132:340–343.
15.
Participants in the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998;83:379–381.
16.
Ørskov H, Thomsen HG, Yde H: Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 1968;219:193–195.
17.
Ørskov H, Christensen NJ: Plasma disappearance rate of injected human insulin in juvenile diabetic, maturity-onset diabetic and nondiabetic subjects. Diabetes 1969;18:653–659.
18.
Fisker S, Frystyk J, Skriver L, Vestbo E, Ho KKY, Ørskov H: A simple, rapid immunometric assay for determination of functional and growth hormone (GH)-occupied GH-binding protein in human serum. Eur J Clin Invest 1996;26:779–785.
19.
Strasburger CJ, Wu Z, Pflaum CD, Dressendorfer RA: Immunofunctional assay of human growth hormone (hGH) in serum: A possible consensus for quantitative hGH measurement. J Clin Endocrinol Metab 1996;81:2613–2620.
20.
Hansen BS, Hjorth S, Welinder BS, Skriver L, De Meyts P: The growth hormone (GH)-binding protein cloned from human IM-9 lymphocytes modulates the downregulation of GH receptors by 22- and 20-kilodalton human GH in IM-9 lymphocytes and the biological effects of the hormone in Nb2 lymphoma cells. Endocrinology 1993;133:2809–2817.
21.
Fisker S, Vahl N, Hansen TB, Jørgensen JOL, Hagen C, Ørskov H, Christiansen JS: Growth hormone (GH) substitution for one year normalises elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial. GH IGF Res 1998;8:105–112.
22.
Hochberg Z, Hertz P, Colin V, Ish Shalom S, Yeshurun D, Youdim MB, Amit T: The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF- I receptors in obesity and anorexia nervosa. Metabolism 1992;41:106–112.
23.
Ørskov H, Seyer-Hansen K: Measurement of and correction for incubation damage in radioimmunoassay. Eur J Clin Invest 1974;4:207–211.
24.
Bristow AF, Gaines Das R, Jeffcoate SL, Schulster D: The First International Standard for Somatropin: Report of an international collaborative study. Growth Reg 1995;5:133–141.
25.
Baumann G: Growth hormone heterogeneity: Genes, isohormones, variants, and binding proteins. Endocrinol Rev 1991;12:424–449.
26.
McCarter J, Shaw MA, Winer LA, Baumann G: The 20,000 Da variant of human growth hormone does not bind to growth hormone receptors in human liver. Mol Cell Endocrinol 1990;73:11–14.
27.
Boguszewski CL, Jansson C, Boguszewski MC, Rosberg S, Wikland KA, Carlsson B, Carlsson LM: Circulating non-22 kDa growth hormone isoforms in healthy children of normal stature: Relation to height, body mass and pubertal development. Eur J Endocrinol 1997;137:246–253.
28.
Albertsson Wikland K, Jansson C, Rosberg S, Novamo A: Time-resolved immunofluorometric assay of human growth hormone. Clin Chem 1993;39:1620–1625.
29.
Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO: Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312–1319.
30.
Jan T, Shaw MA, Baumann G: Effects of growth hormone-binding proteins on serum growth hormone measurements. J Clin Endocrinol Metab 1991;72:387–391.
31.
Yalow RS, Berson SA: Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157–1175.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.